TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15020659
Drug: Bicalutamide 80
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide 80 mg combined with LHRH agonist
Study: 31187203
Drug: LHRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonist monotherapy
Study: 31079973
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus VKA
Study: 31079973
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and clopidogrel plus VKA
Study: 31079973
Drug: No antithrombotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antithrombotic medication
Study: 24736677
Drug: B12 Supplement
Normalized name: Vitamin B12 supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: B12 Supplement (oral cyanocobalamin 6 μg/day)
Study: 20624510
Drug: Combined exercise
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined exercise and cognitive behavioral therapy (EX/CBT)
Study: 18923204
Drug: Per-oral endoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per-oral endoscopic dilatation alone
Study: 15565164
Drug: All trans
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All trans retinoic acid (ATRA) and chemotherapy
Study: 12729868
Drug: Control Therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Therapy (intensive occupational therapy activities)
Study: 10323627
Drug: Topical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical placebo (control)
Study: 6216093
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g mezlocillin three times
Study: 6216093
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g cefuroxime three times
Study: 29480965
Drug: Intercostal nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intercostal nerve block (ICNB) treatment (Group B)
Study: 29480965
Drug: Sufentanil treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil treatment (Group A)
Study: 25444576
Drug: 10 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g/day soluble milk proteins rich in leucine (PRO)
Study: 20194853
Drug: DTIC+IFN‐alpha+Talpha1 (3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIC+IFN‐alpha+Talpha1 (3.2 mg)
Study: 20194853
Drug: DTIC+Talpha1 (3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIC+Talpha1 (3.2 mg)
Study: 20194853
Drug: Talpha1 (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talpha1 (any dosage)
Study: 12385067
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of sublingual stabilized NADH (n = 18)
Study: 12385067
Drug: Identical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo tablets (n = 17)
Study: 10212076
Drug: Cisapride (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (0.2 mg/kg, 8 hourly)
Study: 7754011
Drug: Gd-EOB-DTPA at
Normalized name: Gd-EOB-DTPA
DrugBank: Gadoxetic acid (DB08884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gd-EOB-DTPA at doses of 10, 25, 50, and 100 mumol/kg
Study: 2309538
Drug: Fentanyl (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (10 micrograms.kg‐1 loading dose and 2 micrograms.kg‐1 increments)
Study: 2309538
Drug: Alfentanil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (100 micrograms.kg‐1 initial loading dose and either 20 micrograms.kg‐1 increments or 1 microgram.kg‐1.min‐1 continuous infusion)
Study: 2309538
Drug: Alfentanil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (100 micrograms.kg‐1 initial loading dose)
Study: 25251930
Drug: Rhodiola crenulata/Cordyceps
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhodiola crenulata/Cordyceps sinensis supplementation (1400 mg R + 600 mg C per day)
Study: 22483761
Drug: 0.18% sodium
Normalized name: Dextrose 4% and 0.18% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.18% sodium hyaluronate solution (0.18% SH)
Study: 20447652
Drug: Low-dose quetiapine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose quetiapine (100-400 mg/day)
Study: 8783319
Drug: Proglumide (cholecystokinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proglumide (cholecystokinin antagonist)
Study: 3893508
Drug: Ketotifen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (1 mg orally)
Study: 31126574
Drug: Soy milk
Normalized name: DIMETHICONE 4 g in 100 g CUTANEOUS PATCH [FERMENTED SOY MILK WRINKLE CARE SLEEPING MASK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy milk (240 ml/day for 8 weeks)
Study: 25148829
Drug: ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe 10 mg/day + fenofibrate 200 mg/day
Study: 21801104
Drug: Lidocaine cream
Normalized name: Neomycin and Polymyxin B Sulfates and Lidocaine Cream
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine cream (4% lidocaine)
Study: 21801104
Drug: Lidocaine-prilocaine cream
Normalized name: lidocaine / prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine-prilocaine cream (2.5%)
Study: 16335883
Drug: Telmisartan 40
Normalized name: telmisartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40 mg plus HCTZ 12.5 mg (T40/H12.5)
Study: 16335883
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg plus HCTZ 12.5 mg (T80/H12.5)
Study: 9865456
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intravenous dose of methylprednisolone (Phase II)
Study: 7711991
Drug: sustained-release diltiazem
Normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sustained-release diltiazem 180 mg
Study: 7711991
Drug: sustained-release nicardipine
Normalized name: nicardipine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: sustained-release nicardipine 40 mg
Study: 2403775
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate (30 mg, intramuscularly)
Study: 354483
Drug: tranexamic acid,
Normalized name: Tranexamic Acid, 650 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: tranexamic acid, 6 gm daily for 14 to 21 days
Study: 354483
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (bedrest, dexamethasone when cerebral edema developed, plus isotonic saline)
Study: 28533108
Drug: xylazine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: xylazine (1 mg kg−1) and tiletamine–zolazepam (8 mg kg−1) with hyaluronidase (400 IU)
Study: 28533108
Drug: xylazine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: xylazine (1 mg kg−1) and tiletamine–zolazepam (8 mg kg−1) (control treatment, CON)
Study: 26385029
Drug: Caffeine 200
Normalized name: caffeine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 200 mg twice daily
Study: 25110952
Drug: 6% carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% carbohydrate capsules (CHOc)
Study: 25110952
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (PLAc)
Study: 19320804
Drug: L-arginine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine supplementation during the first 28 days of life
Study: 17300625
Drug: 0 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 ml of soya milk (0 g of fat)
Study: 17300625
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of soya milk (0.32 g of fat)
Study: 17300625
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml of soya milk (1.28 g of fat)
Study: 17300625
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml of soya milk (4.8 g of fat)
Study: 17300625
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml of soya milk (16 g of fat)
Study: 17627399
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment regimens
Study: 9848038
Drug: CSVTCG receptor
Normalized name: Toll-like receptor 9
DrugBank: Toll-like receptor 9 (DB15320)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSVTCG receptor
Study: 28100507
Drug: Iron-supplement bars
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-supplement bars (14 mg Fe/day) for 90 days
Study: 23011357
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) at a dose of 7.5 mg/week over 12-18 months
Study: 11448476
Drug: Etretinate (Tigason)
Normalized name: etretinate
DrugBank: Etretinate (DB00926)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etretinate (Tigason) treatment
Study: 8368641
Drug: LTD4 inhalation
Normalized name: LTD4
DrugBank: Leukotriene D4 (DB11858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTD4 inhalation
Study: 8368641
Drug: PAF inhalation
Normalized name: pafuramidine
DrugBank: Pafuramidine (DB06532)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAF inhalation
Study: 11693896
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg) via 15‐minute intravenous infusion
Study: 11693896
Drug: Pamidronate (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (90 mg) via 2‐hour intravenous infusion
Study: 11693896
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg) and pamidronate
Study: 30802201
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (new tablet)
Study: 30802201
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (original capsule)
Study: 30802201
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations under fed condition
Study: 24589044
Drug: Octenidine wound
Normalized name: octenidine
DrugBank: Octenidine (DB12624)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octenidine wound gel plus modern wound-phase-adapted dressings (treatment arm 2)
Study: 24589044
Drug: Octenidine wound
Normalized name: octenidine
DrugBank: Octenidine (DB12624)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octenidine wound gel alone (treatment arm 3)
Study: 24589044
Drug: Modern wound-phase-adapted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modern wound-phase-adapted dressings alone (treatment arm 1)
Study: 24589044
Drug: Octenidine wound
Normalized name: octenidine
DrugBank: Octenidine (DB12624)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octenidine wound gel treatment (treatment arms 2 and 3)
Study: 16080809
Drug: Irbesartan/HCTZ combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan/HCTZ combination tablets (COAPROVEL)
Study: 12413243
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment 1 (riluzole, dosage not specified)
Study: 12413243
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment 2 (riluzole, dosage not specified)
Study: 31852499
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administration for malaria transmission interruption
Study: 23357841
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg sirukumab
Study: 23357841
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sirukumab
Study: 23357841
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sirukumab
Study: 21258039
Drug: Emulsion combining
Normalized name: propofol lipid emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emulsion combining glycerol and paraffin applied twice daily for 7 days
Study: 21258039
Drug: Emulsion alone
Normalized name: propofol lipid emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emulsion alone (comparator) applied twice daily for 7 days
Study: 19549643
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia PCA with opioids (fentanyl 6 microg ml(‐1) and tramadol 3 mg ml(‐1))
Study: 15631774
Drug: Neurotropin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurotropin (6 ml, IV, QD for 2 weeks, then 2 tablets, BID for another 2 weeks)
Study: 15631774
Drug: Methycobal (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methycobal (1 ml, IM, QD for 2 weeks, then 1 tablet TID for another 2 weeks)
Study: 9210750
Drug: 0.75 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 ml/kg of alcohol
Study: 8135469
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg Aminoglutethimide (AG) daily
Study: 8135469
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg Aminoglutethimide (AG) daily
Study: 8135469
Drug: Cortisone Acetate
Normalized name: Cortisone Acetate
DrugBank: Cortisone (DB14681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cortisone Acetate (CA) replacement dose 37.5 mg/day orally (used in both groups)
Study: 3479419
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin 750 mg bid
Study: 3479419
Drug: Oral ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ofloxacin 400 mg bid
Study: 31077229
Drug: Central BP-guided
Normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central BP-guided treatment
Study: 25458463
Drug: Inhaled glutathione
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled glutathione (GSH)
Study: 23785463
Drug: Streptococcus salivarius
Normalized name: Streptococcus salivarius
DrugBank: Streptococcus salivarius (DB19274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptococcus salivarius M18 (various doses)
Study: 21961534
Drug: Exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise group (EG, n = 52) - supervised aerobic dance and strength training for 60 minutes, twice per week for a minimum of 12 weeks
Study: 19100344
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) for 3 months
Study: 16502768
Drug: EZE/SIMVA 10/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZE/SIMVA 10/10 mg/mg
Study: 16502768
Drug: EZE 10
Normalized name: Angeze 10 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZE 10 mg + SIMVA 10 mg
Study: 16502768
Drug: EZE/SIMVA 10/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZE/SIMVA 10/80 mg/mg
Study: 16502768
Drug: EZE 10
Normalized name: Angeze 10 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZE 10 mg + SIMVA 80 mg
Study: 15337642
Drug: Pharmacotherapy for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy for suicidal behavior
Study: 1998637
Drug: External cephalic
Normalized name: Cephaelis ipecacuanha preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: External cephalic version (ECV) attempted after intravenous injection of 10 micrograms of hexaprenaline.
Study: 389121
Drug: Disulfiram (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram (250 mg)
Study: 19682376
Drug: NP 06‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: NP 06‐1 (Phellodendron amurense bark and Citrus sinensis peel) 740 mg/day (two capsules of 370 mg each, twice daily)
Study: 12385434
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of omeprazole, amoxicillin, and clarithromycin for 1 week
Study: 8556078
Drug: Follicle stimulating
Normalized name: follicle stimulating hormone
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Follicle stimulating hormone (FSH)
Study: 2256497
Drug: Continuous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous oxytocin (intravenous infusion)
Study: 7001489
Drug: Frusemide 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 40 mg twice daily
Study: 7001489
Drug: Frusemide 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 60 mg twice daily
Study: 7001489
Drug: Frusemide 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 80 mg twice daily
Study: 22624284
Drug: RoboLeader (intelligent
Approvals — FDA: no, EMA: no, PMDA: no
Description: RoboLeader (intelligent agent) perfectly reliable
Study: 22624284
Drug: RoboLeader (intelligent
Approvals — FDA: no, EMA: no, PMDA: no
Description: RoboLeader (intelligent agent) false-alarm prone (60% reliability)
Study: 22624284
Drug: RoboLeader (intelligent
Approvals — FDA: no, EMA: no, PMDA: no
Description: RoboLeader (intelligent agent) miss prone (60% reliability)
Study: 22624284
Drug: RoboLeader (intelligent
Approvals — FDA: no, EMA: no, PMDA: no
Description: RoboLeader (intelligent agent) false-alarm prone (90% reliability)
Study: 22624284
Drug: RoboLeader (intelligent
Approvals — FDA: no, EMA: no, PMDA: no
Description: RoboLeader (intelligent agent) miss prone (90% reliability)
Study: 16061831
Drug: PEG-GHRH (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-GHRH (0.25, 0.5, 2 or 4 mg)
Study: 12695732
Drug: Soteria treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soteria treatment (minimal use of antipsychotic medication)
Study: 12695732
Drug: Usual hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual hospital treatment (control)
Study: 1835731
Drug: alpha-interferon (alpha-IFN)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: alpha-interferon (alpha-IFN) at a standard dose of 5 MU QD or 9 MU t.i.w. for at least 1 year
Study: 1835731
Drug: alpha-interferon (alpha-IFN)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: alpha-interferon (alpha-IFN) therapy
Study: 7044880
Drug: 15(R)-15-methyl prostaglandin
Normalized name: 15(S)-15-Methyl Prostaglandin F2α
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15(R)-15-methyl prostaglandin E2 (arbaprostil) 100 microgram capsules, taken four times a day for 28 days
Study: 7044880
Drug: Placebo capsules,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules, taken four times a day for 28 days
Study: 29098261
Drug: Micro-implant anchorage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-implant anchorage
Study: 26207431
Drug: PCEA: Combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA: Combined spinal-epidural anesthesia (CSE) with a PCEA of ropivacaine 0.1% + sufentanil 0.5 μg/mL for 24 hours after CS
Study: 26207431
Drug: ED: CSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ED: CSE with an ED bolus of 3 mg morphine after CS
Study: 26207431
Drug: IT: spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT: spinal anesthesia with an IT bolus of 0.1 mg morphine before CS
Study: 24418597
Drug: Intensive smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive smoking cessation intervention (tailored counselling during face-to-face visits, weekly for the first four weeks, monthly to six months, and two monthly to 12 months)
Study: 22133450
Drug: Wait-listed control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait-listed control group (treatment as usual)
Study: 19648310
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% diclofenac sodium gel (Voltaren Gel)
Study: 12811362
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (250 mL)
Study: 9570605
Drug: 0.5% lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5% lidocaine (30 mg initial bolus, 6 mL)
Study: 9570605
Drug: 5% lidocaine
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lidocaine (30 mg initial bolus, 0.6 mL)
Study: 7923311
Drug: Intra-arterial antibiotic
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial antibiotic infusion therapy (Group A)
Study: 7923311
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion therapy plus percutaneous drainage of the abscess (Group B)
Study: 7923311
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics alone (Group C)
Study: 3144165
Drug: Encainide (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encainide (75 to 240 mg/day)
Study: 30791874
Drug: Social Behaviour
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social Behaviour and Network Therapy
Study: 19922128
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day glatiramer acetate (GA)
Study: 8437319
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual conservative therapy)
Study: 3518048
Drug: Ceftazidime plus
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime plus tobramycin (150 mg/kg body weight/24 h ceftazidime + 10 mg/kg body weight/24 h tobramycin)
Study: 3518048
Drug: Ceftazidime alone
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime alone (150 mg/kg body weight/24 h)
Study: 30898322
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (arm C)
Study: 30578206
Drug: E0302 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: E0302 50 mg intramuscular injection twice a week for 16 weeks
Study: 24120303
Drug: Second-generation antipsychotics
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antipsychotics (risperidone or aripiprazole)